Nantes, France, January 13, 2010 - TcLand Expression SA, a leading company focused on gene expression biomarkers in immunology and personalized medicine today announced the appointment of key opinion leaders to its Scientific and Medical Advisory Board dedicated to Rheumatology.
Chaired by Doctor Pierre Miossec, Professor of Clinical Immunology and Head of the Immunogenetics and Inflammation Department at the Edouard Herriot Hospital of Lyon, France, the board brings together a number of distinguished international experts including Doctor Paul Emery, Head of the Academic Unit of Musculoskeletal Disease at Leeds General Infirmary, UK, Doctor Piet van Riel, Head of the Department of Rheumatology at the University Medical Centre of Nijmegen, The Netherlands, Doctor Sara Marsal, Head of the Rheumatology Research Group at the Vall d’Hebron Hospital, Barcelona, Spain, and Doctor Thierry Lequerré, clinician in the Department of Rheumatology at the University Hospital of Rouen, France.
TcLand Expression has been undertaking pioneering work in the field of Rheumatoid Arthritis with focus on response to biologic therapy. The company is using its expertise and its transcriptomics platform to analyze and discover biomarkers predictive of treatment response. Several patent applications have been made by the company together with the acquisition of licenses from large academic centers. The nomination of a Scientific and Medical Advisory board dedicated to this therapeutic area will reinforce the company’s expertise.
“TcLand Expression confirms today its commitment to lead the field of personalized medicine in immunology and to develop and offer powerful biomarker tools to clinicians and patients. We are extremely pleased to have convinced this group of prominent international scientists and clinicians with valuable experience in the field of Rheumatology to join our Scientific and Medical Advisory Board” stated Alain Huriez, CEO of TcLand Expression. “The Advisory Board’s knowledge and experience will be an integral component to our scientific and clinical development programs and will provide the necessary direction to our pioneering studies.”
Rheumatoid Arthritis
One of the major public health concerns, rheumatoid arthritis is a chronic, progressive, debilitating auto- immune disease that affects approximately 1% of the worldwide population. Despite the important advancements concerning the treatment of Rheumatoid Arthritis during the past 10 years, many patients remain partial responders and true remission is achieved by only a minority. A major goal in the field is thus to predict response to treatment prior to starting a new therapy, in order to optimise patient care, reduce the risk of adverse effects or joint destruction and to positively influence healthcare systems in terms of overall costs.
TcLand Expression
TcLand Expression is a recognized pioneer in the discovery, development and validation of gene expression biomarkers for unmet medical needs in immunology. The company benefits from an exceptional scientific and clinical environment. For more information, please visit our website: www.tcland-expression.com
Contacts
Alain Huriez, CEO TcLand Expression Phone: +33 2 40 35 89 99 ahuriez@tcland-expression.com
Caroline Carmagnol ALIZE RP + 33 6 64 18 99 59 caroline@alizerp.com
